0001213900-11-003768.txt : 20110720 0001213900-11-003768.hdr.sgml : 20110720 20110720150856 ACCESSION NUMBER: 0001213900-11-003768 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110720 DATE AS OF CHANGE: 20110720 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: RADIENT PHARMACEUTICALS Corp CENTRAL INDEX KEY: 0000838879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330413161 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60019 FILM NUMBER: 11977493 BUSINESS ADDRESS: STREET 1: 2492 WALNUT AVENUE STREET 2: STE 100 CITY: TUSTIN STATE: CA ZIP: 92780 BUSINESS PHONE: 7145054460 MAIL ADDRESS: STREET 1: 2492 WALNUT AVENUE STREET 2: STE 100 CITY: TUSTIN STATE: CA ZIP: 92780 FORMER COMPANY: FORMER CONFORMED NAME: AMDL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: CALIFORNIA VENTURES INC DATE OF NAME CHANGE: 19890905 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: WHALEHAVEN CAPITAL FUND LTD CENTRAL INDEX KEY: 0001326903 IRS NUMBER: 980451099 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: P O BOX HM 1027 CITY: HAMILTON STATE: D0 ZIP: HMDX BUSINESS PHONE: 011-441-295-8313 MAIL ADDRESS: STREET 1: P O BOX HM 1027 CITY: HAMILTON STATE: D0 ZIP: HMDX SC 13G/A 1 sc13g0711a1whale_radient.htm AMENDED SCHEDULE 13G sc13g0711a1whale_radient.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)

 
RADIENT PHARMACEUTICALS CORPORATION

(Name of Issuer)
 

COMMON STOCK, $.001 PAR VALUE

(Title of Class of Securities)


750341109

(CUSIP Number)


July 19, 2011

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(c)


*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


(Continued on following page(s)

Page 1 of 4 Pages
 
 
 

 
 
 CUSIP No. 750341109    13G       Page 2 of 4 Pages
 

1.    NAMES OF REPORTING PERSON
                S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Whalehaven Capital Fund Limited

 
2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
                                                                 (a)   o
                                                                 (b)   o

 
3.    SEC USE ONLY

 
4.    CITIZENSHIP OR PLACE OF ORGANIZATION
 
Bermuda

 
5.    SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 7,646,637 Common Stock

 
6.    SHARED VOTING POWER - None

 
7.    SOLE DISPOSITIVE POWER – 7,646,637 shares of Common Stock


8.    SHARED DISPOSITIVE POWER - None

  
9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
 
7,646,637 shares of Common Stock

  
10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  x
 
Excludes shares issuable upon exercise of warrants which warrants contain a 4.99% blocker provision.  Also excludes shares issuable upon conversion of a Promissory Note issued by the Issuer on May 24, 2011 pursuant to a Settlement Agreement dated May 17, 2011 as amended on May 23, 2011, inasmuch as Whalehaven sent a letter to the Issuer on July 19, 2011 and irrevocably relinquished its right to convert the Promissory Note into common stock of the Issuer.

 
11.    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
4.385%

 
12.    TYPE OF REPORTING PERSON
 
CO

  
 
 

 
 
 CUSIP No. 750341109    13G       Page 3 of 4 Pages
 
 
ITEM 1 (a) NAME OF ISSUER: Radient Pharmaceuticals Corporation, a Delaware corporatio

ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

2492 Walnut Avenue, Suite 100, Tustin, CA 92780

ITEM 2 (a) NAME OF PERSON FILING: Whalehaven Capital Fund Limited

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
 
560 Sylvan Avenue, Englewood Cliffs, NJ 07632

ITEM 2 (c) CITIZENSHIP: Bermuda

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.001 par value

ITEM 2 (e) CUSIP NUMBER: 750341109

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B):  Not applicable

ITEM 4 OWNERSHIP

         (a) AMOUNT BENEFICIALLY OWNED: 7,646,637 Shares of Common Stock

         (b) PERCENT OF CLASS: 4.385%

         (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

             (i)   SOLE POWER TO VOTE OR DIRECT THE VOTE

7,646,637 Shares

             (ii)  SHARED POWER TO VOTE OR DIRECT THE VOTE

0 Shares

             (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
 
7,646,637 Shares

             (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

0 Shares
 
 
 

 
 
 CUSIP No. 750341109    13G       Page 4 of 4 Pages
 
 
ITEM 5      OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Whalehaven Capital Fund Limited has fallen below 5%.
 
ITEM 6      OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

ITEM 7      IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

ITEM 8      IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

Not applicable

ITEM 9      NOTICE OF DISSOLUTION OF GROUP
 
Not applicable



SIGNATURE

         After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
   July 19, 2011
   (Date)
   
   /s/ Vadim Mats
   (Signature)
   
   Vadim  Mats, CFO
   (Name/Title)